| |
Large-scale. Long-term. Maintenance studies in major depressive disorder are broad in scope, duration, and size. Build your optimal study plan and mitigate risk with the help of our guide. Learn more. .png)
|
|
Today’s Big NewsOct 9, 2024 |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
| By James Waldron With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has spied an opportunity to scoop up another troubled biotech. |
|
|
|
By Nick Paul Taylor Boehringer Ingelheim has rolled into an alliance with undruggable target specialist Circle Pharma, putting together a package worth up to $607 million to secure the rights to a preclinical cancer program. |
By Gabrielle Masson In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor designed to treat RSV in both kids and adults. |
By Nick Paul Taylor Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on technology to deliver siRNA molecules it discovered using its machine learning platform. |
|
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities. 
|
|
By Fraiser Kansteiner Universal Cells—which Astellas refers to as its cell therapy research organization—is establishing a second location overseas at the Japanese pharma’s research campus in Tsukuba. As part of the move, 17 Universal roles in Seattle are being transferred to the Tsukuba site, while another seven employees are being laid off. |
By Darren Incorvaia London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million ($105 million) cash flow. |
By Darren Incorvaia A day after the Physics prize was given to two scientists for foundational work on machine learning, the Nobel Prize in Chemistry has been awarded to three scientists who used advanced computational methods to solve a decades-old problem. |
By Darren Incorvaia GEMMABio, one of two new companies spun out of the now-folded Gene Therapy Program at the University of Pennsylvania, has announced its first major step in improving global access to rare disease gene therapies. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Fraiser Kansteiner Zealand’s glucagon receptor agonist dasiglucagon has been rebuffed by the FDA once again, scrambling the company's plan to launch the hypoglycemia treatment in kids with congenital hyperinsulinism. |
By Conor Hale Medtronic has been notifying users of its MiniMed insulin pumps to be aware of potentially shortened battery lives, and to heed the devices’ low-power warnings and alerts. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
